文献速递肿瘤 PET/CT神经核医学

68Ga-PSMA-11 PET/CT显像在脑胶质瘤中的应用及其与临床病理预后参数的相关性

68 Ga-PSMA-11 PET/CT Imaging in Brain Gliomas and Its Correlation With Clinicopathological Prognostic Parameters.
PubMed 文献 · Clin Nucl Med · 2023-10-23

本研究为正在进行的前瞻性研究,纳入15例原发或复发胶质瘤患者,比较68Ga-PSMA-11与18F-FDG PET/CT的SUVmax与胶质瘤分级、Ki-67指数及IDH突变状态的关系。结果显示PSMA摄取在高级别肿瘤、IDH野生型及高Ki-67指数者中显著更高,FDG SUVmax亦与这些预后参数显著相关。作者认为PSMA PET可能有助于胶质瘤评估与预后,但样本量小,需更大临床试验得出确证性证据。

要点

  • 68Ga-PSMA-11 PET/CT在全部高级别胶质瘤中显示摄取,2/3低级别胶质瘤无PSMA摄取。
  • PSMA SUVmax在更高分级肿瘤、IDH突变野生型及更高Ki-67指数者中显著更高。
  • FDG PET SUVmax亦与这些预后参数显著相关。

核心结论

  • 在这项初步结果中,PSMA PET似乎是胶质瘤评估和预后的一项重要工具。
  • PSMA靶向诊疗可作为一种个体化方法在PSMA高摄取的胶质瘤中进行探索。
  • 受小样本量限制,需更大规模的临床试验才能得出确证性证据。

研究设计与样本

  • 本研究为正在进行的前瞻性研究,经机构科学与医学伦理委员会批准。
  • MRI显示原发或复发胶质瘤病灶的患者接受区域脑68Ga-PSMA-11与18F-FDG PET/CT扫描。
  • 最终组织病理学(胶质瘤分级)、Ki-67指数及IDH突变状态与68Ga-PSMA-11和18F-FDG PET/CT的SUVmax进行比较。
  • 共纳入15例患者(13例男性、2例女性;年龄范围21-73岁;中位年龄58岁)。
  • 15例中10例为初治、2例为复发胶质瘤;最终组织病理学显示3例为WHO I-II级、6例为III级、6例为IV级(多形性胶质母细胞瘤)。

主要发现

  • 68Ga-PSMA-11 PET/CT在全部高级别胶质瘤中显示示踪剂摄取,肿瘤/本底比值良好。
  • 68Ga-PSMA-11在2/3低级别胶质瘤中无PSMA摄取,在1/3患者中显示低级别摄取。
  • PSMA表达(以SUVmax值评估)在更高分级肿瘤、IDH突变野生型状态及更高Ki-67指数者中显著更高。
  • FDG PET SUVmax亦与这些预后参数显示显著相关。

临床怎么用

  • 作者认为PSMA PET可能是胶质瘤评估和预后的一项重要工具。
  • 作者提出PSMA靶向诊疗可作为一种个体化方法在PSMA高摄取的胶质瘤中进行探索。
  • 作者指出受小样本量限制,需更大规模的临床试验才能得出确证性证据。

局限性

  • 原文指出局限性为小样本量。
  • 原文结论指出需更大规模的临床试验才能得出确证性证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Gliomas are the most common primary central nervous system tumors, of which the malignant gliomas account for 60%-75%. The primary and secondary brain malignancies are highly treatment resistant, and their marked angiogenesis attracts interest as a potential therapeutic target. The grade of gliomas, Ki-67 index, and IDH mutation status are among the major prognostic markers in gliomas. Prostate-specific membrane antigen (PSMA) is a zinc-dependent peptidase that is not only expressed in prostate cancer cells but also in the tumor neovasculature. The initial PSMA PET studies in central nervous system tumors using 68 Ga-HBED-CC-PSMA ( 68 Ga-PSMA-11) PET tracer confirmed selective target expression in gliomas of different grades, with higher expression in high-grade glioma compared with low-grade glioma. AIMS AND OBJECTIVES: The aim of the present study was to correlate and compare the 68 Ga-PSMA-11 and 18 F-FDG uptake in brain tumors with their clinicopathological prognostic parameters, so as to study their prognostic implications. In addition, the study also aimed to identify patients who are likely to benefit from potential PSMA-targeted therapies. PATIENTS AND METHODS: This ongoing prospective study was approved by the institutional scientific and medical ethics committee. The patients with primary or recurrent glioma lesions on MRI underwent regional brain PET/CT scanning with 68 Ga-PSMA-11 and 18 F-FDG. The final histopathology of the brain lesions (glioma grade), Ki-67 index, and IDH mutation status were compared with SUV max values of the 68 Ga-PSMA-11 and 18 F-FDG PET/CT. RESULTS: A total of 15 patients (13 males and 2 females; age range, 21-73 years; median age, 58 years) were included in this study analysis. Among the 15 patients, 10 were treatment naive and 2 were patients with recurrent glioma. Three patients turned out to be WHO grade I-II, 6 belonged to grade III, and 6 grade IV (glioblastoma multiforme) on final histopathology. The 68 Ga-PSMA-11 PET/CT showed tracer uptake in all high-grade gliomas with good tumor-to-background ratio. It was PSMA nonavid in 2/3 low-grade gliomas, and it showed low-grade uptake in 1/3 patients. PSMA expression (as evaluated by SUV max values) was significantly higher in higher-grade tumors, those with IDH mutation wildtype status, and higher Ki-67 indices. FDG PET SUV max also showed significant correlation with these prognostic parameters. CONCLUSIONS: In these preliminary results, PSMA PET appears to be an important tool in the evaluation and prognosis of gliomas. PSMA-directed theranostics can be explored as a personalized approach in gliomas with high PSMA uptake. However, with the limitation of small sample size, larger clinical trials are warranted to draw conclusive evidence regarding the same.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Verma P, Singh BK, Sudhan MD, et al. 68 Ga-PSMA-11 PET/CT Imaging in Brain Gliomas and Its Correlation With Clinicopathological Prognostic Parameters. Clin Nucl Med. 2023. PMID: 37883060. doi:10.1097/RLU.0000000000004903

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。